Market research
PBP.AU Probiotec Limited
AU AUD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 242M
- P/E ratio
- 29.8
- Analyst target
- 3
- Dividend yield
- 2.4%
- Beta
- 0.47
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000PBP7
- Market cap
- 242M
- P/E ratio
- 29.8
- Analyst target
- 3
- Dividend yield
- 2.4%
- Beta
- 0.47
About
About Probiotec Limited
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia. As of June 18, 2024, Probiotec Limited operates as a subsidiary of PYFA Australia Pty Ltd.
Research context
Probiotec Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PBP.AU discussion.
5 years, 6 months ago
Probiotec Limited is currently in a long term downtrend where the price is trading 2.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Probiotec Limited's total revenue sank by 3.5% to $43M since the same quarter in the previous year.
Its net income has increased by 79.1% to $1M since the same quarter in the previous year.
Finally, its free cash flow grew by 1252.5% to $3M since the same quarter in the previous year.
Based on the above factors, Probiotec Limited gets an overall score of 3/5.